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Abstract
Purpose The purpose of the study is to validate a method that
provides the opportunity to distinguish a balanced translocation
carrier embryo from a truly normal embryo in parallel with
comprehensive chromosome screening (CCS).
Methods A series of translocation carrier couples that underwent
IVF with single nucleotide polymorphism (SNP) array-based
CCS on 148 embryos were included. Predictions of balanced
or normal status of each embryo were made based upon embry-
onic SNP genotypes. In one case, microdeletion status was used
to designate whether embryos were balanced or normal. In 10
additional cases, conventional karyotyping was performed on
newborns in order to establish the true genetic status (balanced
or normal) of the original transferred embryo. Finally, implanta-
tion potential of balanced or normal embryos was compared.
Results Phasing SNPs using unbalanced embryos allowed ac-
curate prediction of whether transferred embryos were balanced
translocation carriers or truly normal in all cases completed to
date (100 % concordance with conventional karyotyping of
newborns). No difference in implantation potential of balanced
or normal embryos was observed.
Conclusions This study demonstrates the validity of a CCS
method capable of distinguishing normal from balanced
translocation carrier embryos. The only prerequisite is the avail-
ability of parental DNA and an unbalanced IVF embryo, mak-
ing the method applicable to the majority of carrier couples. In
addition, the SNP array platform allows simultaneous CCS for
aneuploidy with the same platform and from the same biopsy.
Future work will involve prospective predictions to select nor-
mal embryos with subsequent karyotyping of the resulting
newborns.
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Introduction
Very few causes of infertility or recurrent pregnancy loss can
be explained by a clear genetic origin. Chromosomal rear-
rangements represent one such cause with carrier patients
experiencing an increased rate of failure to achieve a pregnan-
cy and likelihood of having a miscarriage due to the unbal-
anced transmission of derivative chromosomes to gametes
and offspring. One option available to these individuals is
provided by in vitro fertilization (IVF) with preimplantation
genetic testing (PGT). Embryos that inherit an unbalanced
karyotype can be readily identified through a variety of testing
methods including fluorescence in situ hybridization, array
comparative genomic hybridization, and single nucleotide
polymorphism microarrays.
The array-basedmethods of testing provide the added benefit
of screening for whole chromosome aneuploidy of all 24 chro-
mosomes (22 autosomes, X and Y) in parallel with the identifi-
cation of unbalanced inheritance of chromosomes from the
translocation [1–5]. Several randomized controlled trials have
already demonstrated that comprehensive chromosome
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screening (CCS) for aneuploidy significantly improves clinical
outcomes [6–9] such that the same improvement can be expect-
ed when applied to patients who carry a balanced translocation.
Previous studies investigating the application of array-based
CCS methods in patients with translocations indicate similar
maternal age-related increase in aneuploidy of chromosomes
unrelated to the translocation chromosomes. In addition, these
studies have also helped determine the resolution of detection of
segmental aneuploidies associated with the translocation [10].
Unbalanced embryos and embryos with aneuploidy for other
chromosomes can be identified and excluded from selection
for embryo transfer in order increase success rates and avoid
chromosomally related pregnancy loss.
One of the remaining challenges to PGTwith CCS in em-
bryos derived from translocation carrier patients is the inabil-
ity to distinguish an embryo that is a carrier of the balanced
translocation from one that is truly normal [11]. Current
methods are therefore unable to prevent inheritance of the
balanced translocation in the children born following IVFwith
PGT and CCS. Many patients would prefer to avoid transmit-
ting their translocation and its associated risk of infertility and
miscarriage to their offspring. This is particularly true if no
additional cost were to be incurred in the process of making a
distinction between the two types of embryos.
Despite this, it has remained challenging to distinguish be-
tween a balanced translocation carrier embryo and one that is
truly normal while also providing CCS for aneuploidy in par-
allel. This is in part due to the indistinguishable nature of the
results obtained from either type of embryo. Both a balanced
translocation carrier embryo and one that is truly normal dis-
play the same copy number neutrality. That is, when the copy
number analysis is obtained from array-based methods com-
monly used for testing, both types of samples give the exact
same profile, a copy number of 2.
A previously validated quantitative SNP array-based CCS
method [12] can reliably provide both copy number and
genotyping data and has demonstrated the ability to resolve
segmental aneuploidies as small as 2.36 Mb for translocation
patients [5, 13]. This unique ability may enable distinguishing
balanced from normal embryos while also providing CCS. In
a manner very similar to establishing linkedmarkers for single
gene disorder PGD, SNPs which are near the translocation
breakpoints and also heterozygous (two different alleles) in
the carrier parent, and homozygous in the partner, could be
used to track which chromosomes are inherited in the copy
number neutral (normal or balanced) embryos by determining
which of the two alleles are present. Unbalanced embryos
could also be used to determine which of the two alleles are
linked to the derivative or to the normal chromosomes. The
ability to predict actual status from embryo biopsies could
then be validated by a blinded comparison to conventional
karyotypes performed on children born after IVF and PGT
with this SNP array methodology.
Materials and methods
Strategy
This study was organized into three phases. Phase 1 involved
evaluating whether the method (Fig. 1) of predicting balanced
or normal embryos was consistent with the presence of a
microdeletion in a previously published case. In this case,
unlike most translocation cases, a microdeletion near the
breakpoint of one of the translocations was present in the
patient and known to cause Alagille syndrome. If present in
an embryo, the microdeletion would indicate that it was also a
carrier of the translocation. Phase 2 involved using the same
method to make predictions in a series of more conventional
translocation patients who had already undergone IVF with
PGT and embryo transfer of a balanced/normal embryo.
Newborn karyotypes were obtained to determine the true sta-
tus of the embryos (balanced or normal) in order to evaluate
the level of concordance of the SNP genotyping methodology
of prediction from the original embryo biopsy. Phase 3 in-
volved using the validated prediction method to determine
whether balanced carrier embryos implant less often than truly
normal embryos.
SNP array analyses
Default settings of GTYPE were used to obtain genotypes for
parental DNA using the Affymetrix NspI GeneChip as recom-
mended by the supplier. BInformative^ SNPs were defined as
those that were heterozygous in the carrier patient and homo-
zygous in the partner within 5 Mb of the breakpoints for each
chromosome involved in the translocation. This distance was
chosen in order to avoid misinterpretation from possible re-
combination events that might occur during meiosis in the
carrier patient’s gametes.
Embryo trophectoderm biopsies were processed with
whole genome amplification (WGA) and SNP array analysis
as previously described [12]. The same informative SNPs
were compared between embryos identified as copy number
normal (balanced/normal) to embryos identified as unbal-
anced. An example of this process is illustrated in Fig. 1.
Genotyping was performed with settings of GTYPE as previ-
ously described. Briefly, settings were adjusted in order to
obtain more accurate genotype predictions but with fewer
successful genotypes per SNP tested. Unbalanced embryos
that possessed one normal chromosome and one derivative
chromosome were identified using copy number analysis as
previously described. When a chromosome from a balanced/
normal embryowas found to bemore similar to an unbalanced
embryo derivative chromosome, the embryo was predicted to
be a carrier of the balanced translocation. When a chromo-
some from a balanced/normal embryo was found to be more
similar to an unbalanced embryo normal chromosome, the
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embryo was predicted to be normal. In each case, the
balanced/normal embryo provided two measurements of sim-
ilarity, one for each of the two chromosomes involved in the
translocation. In addition, when multiple unbalanced embryos
were available for comparison, all such comparisons were
performed.
Newborn karyotyping
Children born following the conventional use of SNP
array-based testing for CCS and unbalanced transloca-
tions had conventional G-banding karyotypes performed
from peripheral blood. Reports were obtained and then
compared to the blinded predictions made from SNP




In order to establish the potential validity of the pro-
posed methodology, a specific case with previously
published data was used prior to recruiting new patients
to participate. Since this particular case had a unique
microdeletion associated with the balanced translocation,
newborn karyotyping was not needed in order to have a
way to determine the actual status of each embryo (bal-
anced or normal). That is, in each embryo, the presence
or absence of the microdeletion could be used to deter-
mine whether the embryo was a carrier of the balanced
translocation or normal, respectively. In this case, a total
of 12 embryos were originally found to be balanced or
normal using the conventional copy number analysis of
the SNP array data. Informative SNPs within 5 Mb of
the breakpoints on each of the two chromosomes in-
volved in the translocation were identified by analysis
of parental DNA. A comparison of the genotypes at
these informative SNP positions was performed for each
balanced/normal embryo against all possible unbalanced
embryos. In 10 cases, the similarities indicated that the
embryos were normal, and in 2 cases, the embryos were
consistent with a balanced translocation carrier status.
The microdeletion status of each of the balanced/
normal embryos was then unblinded and compared to
the SNP genotyping-based predictions. All 12 cases
were concordant. Therefore, the first phase of this study
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1. Obtain genotypes on parental DNA
2. Perform CCS on embryo biopsies
3 copies 1 copy
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3. Evaluate concordance of informative SNPs 
If the normal/balanced embryo’s example informative SNP genotype on chr4 
matches the example unbalanced embryo’s genotype then it is normal, if not, 
then it is a carrier of the balanced translocation
or
Fig. 1 Workflow diagram for
using SNP genotyping
information from parental DNA
and an unbalanced embryo to
determine the carrier status of
copy number neutral embryos
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indicated 100 % accuracy of using unbalanced embryos
and SNP genotyping analyses to predict whether
balanced/normal embryos were actually balanced car-
riers or truly normal.
Phase 2
Based upon these findings, 10 patients who had already
undergone IVF with SNP array-based testing of their
embryos for CCS and unbalanced translocations were
successfully recruited. Informative SNPs within 5 Mb
of the breakpoints in embryos which were selected for
transfer and led to delivery were then evaluated against
unbalanced embryos from the same patient. In 2 cases,
the embryos were predicted to be carriers of a balanced
translocation, and in 8 cases as truly normal. Karyotypes
were obtained from newborns in each of the 10 cases
and confirmed the embryo SNP genotyping-based predic-
tion of the genetic status of the embryo in all cases
(100 % concordance).
Phase 3
Having validated the ability to distinguish balanced from nor-
mal embryos using SNP genotyping from an embryo biopsy,
we applied the technique to evaluate the implantation potential
of both types of embryos. Out of 126 embryos evaluated, 62
(49 %) were predicted to be normal and 64 (51 %) were
predicted as balanced carriers of a translocation. Forty-two
(68 %) of the 62 normal embryos and 38 (59 %) of the 64
carrier embryos successfully implanted, which was not signif-
icantly different (chi-square p value=0.33). Maternal age and
number of oocytes retrieved were also not significantly differ-
ent amongst the two groups of embryos.
Discussion
IVF with PGT has provided a powerful option for couples
who carry a balanced translocation and has allowed them to
avoid experiencing miscarriages due to unbalanced embryos.
Without the benefit of a conventional karyotype to see the
structure of the rearrangement, it has been impossible to make
a prediction of whether the embryo is balanced vs. normal
while also providing CCS data. Even arguably more powerful
technologies like next-generation sequencing would not be
able to solve this problem as they would predict a copy num-
ber of 2 in either case for the affected chromosomes.
Therefore, despite having a successful IVF cycle and delivery,
many of these couples will be passing on the translocation to
their children who may also be subjected to infertility, recur-
rent pregnancy loss, and, perhaps, have to use assisted repro-
ductive technologies to conceive. The couples who
participated in this IRB-approved study all expressed a desire
to select against the translocation and remove it from their
reproductive lineage, sparing their future children of the re-
productive challenges they faced. To date, this option has not
been reliably available.
Using a SNP array platform for CCS allows reliable differ-
entiation between balanced and normal embryos without signif-
icant additional testing or expense. New probes do not need to
be developed and treatment need not be delayed. Rather SNP
genotyping data from the parents can be used in combination
with the data from unbalanced embryos to provide a prediction
prior to frozen embryo transfer. Ongoing research will continue
to further validate this approach. However, the blinded predic-
tion being correct in 10 out of 10 cases, which would be 1024 to
1 odds of happening by chance, is very reassuring.
Interestingly, approximately half of the transferred embry-
os were normal vs. balanced indicating that morphology-
based selection from amongst the transferrable embryos will
not reliably select against the balanced translocation. There
was a small, but not significant, increase in implantation rates
amongst normal embryos; ongoing research will continue to
evaluate whether there is a significant difference. This method
relies on the availability of an unbalanced embryo being pres-
ent. In those cases without an unbalanced embryo, the couple
could choose to transfer one by morphology and the karyo-
type of the newborn could be used tomake predictions prior to
subsequent transfers.
This study provides validation for a method capable of
providing both CCS and the ability to identify embryos that
are carriers of balanced translocations.While much of the field
of PGS has moved to non-genotyping-based methods of CCS
(qPCR and array CGH), this study demonstrates a unique
application for SNP array-based testing in embryos from pa-
tients carrying a balanced translocation.
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